{
    "Clinical Trial ID": "NCT01209195",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Part 1: Dose Escalation: Cohort 1",
        "  MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV",
        "INTERVENTION 2: ",
        "  Part 1: Dose Escalation: Cohort 2",
        "  MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV",
        "  Paclitaxel - 80mg/m2 weekly IV"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Cytological or histological confirmation of locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or endometrial cancer; OR, cytological or histological confirmation of locally advanced /metastatic Her2 non-overexpressing breast cancer",
        "  Eighteen years of age or above",
        "  Candidates for chemotherapy",
        "  Able to understand and sign an informed consent (or have a legal representative who is able to do so)",
        "  Measurable disease according to RECIST v1.1",
        "  ECOG Performance Score (PS) of  2",
        "  Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-121",
        "Exclusion Criteria:",
        "  Prior radiation therapy to >25% of bone marrow-bearing areas",
        "  Evidence of any other active malignancy",
        "  Active infection or fever> 38.5\u00b0C during screening visits or on the first scheduled day of dosing",
        "  Symptomatic CNS disease",
        "  Known hypersensitivity to any of the components of MM-121 or who have had hypersensitivity reactions to fully human monoclonal antibodies",
        "  Received treatment, within 30 days prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state",
        "  Pregnant or breast feeding"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting Toxicity (DLT)",
        "  To establish the safety of escalating doses of MM-121 in combination with paclitaxel in order to determine the recommended phase 2 dose. Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose. Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD.",
        "  Time frame: From date of first dose to 30 days after termination, the longest 163 weeks",
        "Results 1: ",
        "  Arm/Group Title: Part 1: Dose Escalation: Cohort 1",
        "  Arm/Group Description: MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV",
        "  Overall Number of Participants Analyzed: 7",
        "  Measure Type: Number",
        "  Unit of Measure: participants reporting DLTs  0",
        "Results 2: ",
        "  Arm/Group Title: Part 1: Dose Escalation: Cohort 2",
        "  Arm/Group Description: MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV",
        "  Paclitaxel - 80mg/m2 weekly IV",
        "  Overall Number of Participants Analyzed: 3",
        "  Measure Type: Number",
        "  Unit of Measure: participants reporting DLTs  1"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 4/10 (40.00%)",
        "  SMALL INTESTINAL OBSTRUCTION *  [1]3/10 (30.00%)",
        "  INTESTINAL OBSTRUCTION *  [1]1/10 (10.00%)",
        "  INTESTINAL PERFORATION *  [1]1/10 (10.00%)",
        "  ABDOMINAL PAIN *  [1]0/10 (0.00%)",
        "  DIARRHOEA *  [1]0/10 (0.00%)",
        "  GASTRITIS *  [1]0/10 (0.00%)",
        "  PEPTIC ULCER *  [1]0/10 (0.00%)",
        "  DEATH *  [1]1/10 (10.00%)",
        "  DISEASE PROGRESSION *  [1]0/10 (0.00%)",
        "Adverse Events 2:",
        "  Total: 12/31 (38.71%)",
        "  SMALL INTESTINAL OBSTRUCTION *  [1]0/31 (0.00%)",
        "  INTESTINAL OBSTRUCTION *  [1]0/31 (0.00%)",
        "  INTESTINAL PERFORATION *  [1]0/31 (0.00%)",
        "  ABDOMINAL PAIN *  [1]1/31 (3.23%)",
        "  DIARRHOEA *  [1]1/31 (3.23%)",
        "  GASTRITIS *  [1]1/31 (3.23%)",
        "  PEPTIC ULCER *  [1]1/31 (3.23%)",
        "  DEATH *  [1]0/31 (0.00%)",
        "  DISEASE PROGRESSION *  [1]3/31 (9.68%)",
        "  FATIGUE *  [1]2/31 (6.45%)"
    ]
}